Del Monte Foods files for bankruptcy; SGX-listed parent has over US$700 million exposure to US unit
In statements issued on Wednesday (Jul 2), Singapore and Philippine-listed DMP said it would have to deconsolidate Del Monte Foods (DMF) from its accounts as it no longer controls the US subsidiary, which has filed for bankruptcy.
DMP in June elected to skip a payment to the US unit's lenders as part of a lawsuit settlement tied to a controversial debt restructuring. This led to the lenders appointing a majority of DMF's board members and 25 per cent of DMP's stake in DMF was transferred to them.
DMP said the loss of control over DMF led to the deconsolidation of the subsidiary from its financial statements. According to the parent's annual report for FY2024, DMF's US$1.7 billion of sales accounted for over 70 per cent of DMP's group sales. The group has been posting significant losses in its last few quarters
The group is currently assessing the financial impact of this change, noting that its net investment in DMF was valued at US$579 million as of 31 January 2025, with an additional US$169 million in net receivables from DMF and its subsidiaries. The impairment value will be finalised following an audit.
DMF entered a restructuring agreement with lenders and started voluntary Chapter 11 proceedings to implement its terms, securing a commitment for US$912.5 million in debtor-in-possession financing, inclusive of US$165 million in new funding, from certain existing lenders.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
A filing with the US Bankruptcy Court states that the company has both liabilities and assets estimated between US$1 billion and US$10 billion.
DMF executed a debt overhaul last year, which became the subject of a lawsuit by left-behind lenders who said the company defaulted on a US$725 million financing agreement when it shifted the assets away from the reach of lenders.
The strategy – known in industry parlance as a drop-down transaction – allowed Del Monte Foods to raise fresh liquidity by borrowing against the transferred assets. The deal also prioritised participating lenders via debt swaps and created different payment priorities, Bloomberg reported.
DMF said in a statement that the restructuring support agreement contemplates the company undertaking a going-concern sale process for all or substantially all of its assets. Financing along with cash from ongoing operations is expected to provide sufficient liquidity during the sale process and fund ongoing operations, as it intends to keep serving customers, according to the statement.
DMP shares resumed trading yesterday after a trading halt on Tuesday. The counter plunged over 9 per cent to S$0.058 by yesterday afternoon in active trading.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
an hour ago
- Business Times
Philippines' inflation at 1.4% in June
[MANILA] Philippine inflation slightly quickened to 1.4 per cent in June, compared to the previous month's 1.3 per cent, the statistics agency said on Friday, due to the faster pace of increases in utility costs. Economists in a Reuters poll had expected inflation of 1.5 per cent last month, within the central bank's forecast range of 1.1 to 1.9 per cent. Core inflation, which strips out volatile food and energy prices, was unchanged at 2.2 per cent in June. Inflation in the first half of the year averaged 1.8 per cent, within the central bank's 2 per cent to 4 per cent target for the year. REUTERS
CNA
2 hours ago
- CNA
Philippine annual inflation at 1.4% in June
MANILA :Philippine annual inflation slightly quickened to 1.4 per cent in June, compared to the previous month's 1.3 per cent print, the statistics agency said on Friday, due to the faster pace of increases in utility costs. Economists in a Reuters poll had expected annual inflation of 1.5 per cent last month, within the central bank's forecast range of 1.1 to 1.9 per cent. Core inflation, which strips out volatile food and energy prices, was unchanged at 2.2 per cent in June. Inflation in the first half of the year averaged 1.8 per cent, within the central bank's 2 per cent to 4 per cent target for the year.
Straits Times
15 hours ago
- Straits Times
Hong Kong-listed Chinese pharma sets sights on SGX for secondary listing
Sign up now: Get ST's newsletters delivered to your inbox The proposed listing will not involve issuing new shares, and China Medical System will continue to be primarily traded in Hong Kong. SINGAPORE – A Hong Kong-listed pharmaceutical company is aiming to launch a secondary listing on the Singapore Exchange (SGX) later this month. China Medical System (CMS) filed its preliminary prospectus with the Monetary Authority of Singapore on June 27. The proposed listing will not involve issuing new shares, and CMS will continue to be primarily traded in Hong Kong, where it listed in 2010. CMS said Singapore is the 'ideal launch place' for its high-value innovations given the country's highly developed economy, robust IP protections, skilled talent pool and trade agreements. It will use Singapore as a base to expand across South-east Asia and the Middle East, while employing the listing here to attract funds. 'The SGX listing marks a strategic step to deepen our regional footprint, boost visibility among South-east Asian stakeholders, and reinforce our reputation as a high-quality, innovation-led pharmaceutical player,' the company said. It added that its regional expansion is being driven by the need to bolster supply chains. CMS, which was set up in 1992, produces around 40 products that focus on three areas of healthcare: Cardio-cerebrovascular and gastroenterology; dermatology and medical aesthetics; and ophthalmology. Its financial performance in 2023 and 2024 was impacted by a new policy in China that centralised bidding and consolidated procurement processes in order to lower drug and medical device costs for public hospitals. Three of CMS's drugs fell under the new regulations but revenue rebounded in the second half of last year, allowing the firm to post profits of 1.61 billion yuan (S$290 million) in 2024. The company highlighted four key platforms to boost its presence across Asia-Pacific, including its research and development arm and PharmaGend, the firm's development and manufacturing platform for regional manufacturing and supply. In December 2023, PharmaGend acquired a manufacturing facility in Tuas, which is expected to ship its first productions for the US market in the second half of this year. CMS said it plans to add to its 200-strong workforce here, and will also outlay US$200 million to double capacity at the Tuas plant, a project that is expected to be fully operational by the end of 2028. The firm stated that the Singapore facility, which can produce one billion tablets a year, eases supply chain risks by localising production for regional and Middle East markets. 'This aligns with Asean's push for self-sufficiency in essential medicines and positions CMS as a reliable partner in regional health security,' it added. South-east Asia's pharmaceutical market is projected to hit a volume of US$18.28 billion by 2030, with an annual growth of 4.9 per cent. The CMS listing will be the second on the mainboard this year, after the initial public offering of local firm Info-Tech Systems, which begins trading on July 4. Last week, Japan's telco giant Nippon Telegraph and Telephone filed its preliminary prospectus for a data centre Reit, which could mark SGX's largest Reit listing since 2013.
